BridgeBio Pharma
BBIO
BBIO
262 hedge funds and large institutions have $4.85B invested in BridgeBio Pharma in 2024 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 104 increasing their positions, 78 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
11% more capital invested
Capital invested by funds: $4.36B → $4.85B (+$483M)
4% more funds holding
Funds holding: 251 → 262 (+11)
2.31% more ownership
Funds ownership: 91.17% → 93.48% (+2.3%)
Holders
262
Holding in Top 10
15
Calls
$389M
Puts
$77.2M
Top Buyers
| 1 | +$67.2M | |
| 2 | +$34.6M | |
| 3 | +$25.8M | |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$25M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$24.1M |
Top Sellers
| 1 | -$46.3M | |
| 2 | -$27.3M | |
| 3 | -$25.2M | |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$21.1M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$18.8M |